Sharemaestro Newsreel

Natera Inc (NTRA) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Natera Inc (NTRA), detailing its current risk score, beta value, and various volatility and drawdown metrics. Natera Inc holds a risk assessment score of 8.37, ranking 12th in the Healthcare Providers & Services industry, with a beta …

Qiagen (QGEN) Projected to Post Quarterly Earnings on Wednesday

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

Adaptive Biotechnologies (ADPT) came out with a quarterly loss of $0.1 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.17 per share a year ago. These figures are adjusted for non-recurring items. This quarterly …

Icon PLC (ICLR) Lags Q2 Earnings Estimates

NeoGenomics (NASDAQ:NEO) Hits New 1-Year High After Better-Than-Expected Earnings

Mettler-Toledo (MTD) Q2 Earnings: What To Expect

BillionToOne: The Guidance Looks Conservative, The Price Does Not (NASDAQ:BLLN)

Charles River Laboratories (CRL) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release

IDEXX Laboratories (IDXX) Could Be 20% Below Fair Value On Its Diagnostics Growth Story

Wall Street's Insights Into Key Metrics Ahead of Guardant Health (GH) Q2 Earnings

Guardant Health (GH) Q2 Earnings Report Preview: What To Look For

OPKO Health gives back 17% after sharp post-earnings surge (OPK:NASDAQ)

Why NeoGenomics (NEO) Stock Is Up Today

Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Medpace Holdings, Inc. (MEDP) and Encourages Investors to Learn More About the Investigation

Bronstein, Gewirtz & Grossman, LLC has launched an investigation into Medpace Holdings, Inc. (NASDAQ: MEDP) concerning potential corporate wrongdoing by the company and its officers/directors. The firm is encouraging investors who purchased Medpace securities before April 22, 2025, and still hold them, to join …

IDEXX Laboratories Inc (IDXX) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for IDEXX Laboratories Inc (IDXX), detailing its volatility, financial risk, and investment risk. The company has a current risk assessment score of 7.69, ranking 31st in the Healthcare Equipment & Supplies industry, and a beta value of 1.56, …

Qiagen NV (QGEN) Financial Health: Profitability & Balance Sheet Analysis

The article provides an analysis of Qiagen NV (QGEN)'s financial health, indicating a stable financial status and high operating efficiency with a current financial score of 8.79. The company reported a 1.83% year-over-year increase in quarterly revenue, reaching 492.32M, and a 25.03% year-over-year increase …

Danaher Corp (DHR) Institutional Confidence

Danaher Corp (DHR) has an institutional shareholding score of 7.00, placing it 78th in the Healthcare Equipment & Supplies industry. This score reflects an institutional shareholding proportion of 83.99%, which decreased by 0.84% quarter-over-quarter. The largest institutional shareholder is Al Gore, holding 7.97M shares, …

How Waters’ New Xevo IVD Mass Spectrometer Could Shape Its Clinical Diagnostics Strategy (WAT)

NeoGenomics Inc (NEO) Q2 2026 Earnings Call Highlights: Strong Revenue Growth and Raised ...

NeoGenomics Inc (NEO) reported strong Q2 2026 results with an 11% year-over-year revenue growth to $201.7 million, driven by robust clinical and Next-Generation Sequencing (NGS) performance. The company raised its full-year 2026 revenue guidance to $802 million to $806 million and adjusted EBITDA guidance …

ATYR|aTyr Pharma Inc|Price:0.499|Chg%:+0.010

This article presents a comprehensive stock analysis of aTyr Pharma Inc (ATYR) by TradingKey, highlighting its fundamental stability, high growth potential, and a fairly valued assessment within the Biotechnology & Medical Research industry. Despite recent weak stock market performance, the company shows strong fundamentals …

OPK|OPKO Health Inc|Price:1.650|Chg%:+0.410

This article provides a comprehensive stock analysis of OPKO Health Inc (OPK), highlighting its healthy fundamentals, significant growth potential, and fair valuation within the Healthcare Providers & Services industry. It notes high institutional ownership and recent "Buy" ratings from analysts, with expectations for the …

Medpace Holdings Inc (MEDP) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Medpace Holdings Inc (MEDP), detailing its current price momentum, support and resistance levels, and various technical indicators. It presents a summary of buy, sell, and neutral signals based on indicators like MACD, RSI, KDJ, and moving averages. …

Fulgent Genetics Inc (FLGT) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a risk assessment for Fulgent Genetics Inc (FLGT), noting its score of 6.80, which ranks 25 out of 75 in the Healthcare Providers & Services industry. The company's beta of 0.93 indicates it tends to underperform in up markets but decline …

IMUX|Immunic Inc|Price:13.271|Chg%:-0.539

This article provides a detailed stock analysis of Immunic Inc (IMUX) based on TradingKey's comprehensive stock score. It highlights Immunic's strong fundamentals and high growth potential, noting it's fairly valued within the Biotechnology & Medical Research industry. The analysis also covers high institutional ownership …

Veracyte Inc (VCYT) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Veracyte Inc (VCYT), detailing its current price momentum score, support and resistance levels, and insights from various technical indicators and moving averages. The analysis suggests VCYT is suitable for range-bound swing trading, with indicators showing mixed signals …

Myriad Genetics (MYGN) Reports Q2: Everything You Need To Know Ahead Of Earnings

Myriad Genetics (MYGN) is set to report Q2 earnings this Thursday, with analysts expecting a 2.5% year-on-year revenue decline. The company missed revenue expectations last quarter, and its stock is down 9.5% over the last month, contrasting with a 4.4% average rise in the …

Why is Solventum stock surging today?

Solventum stock surged over 7% today after UBS upgraded the healthcare company from Neutral to Buy, setting a price target of $95. This upgrade, combined with supportive analyst sentiment and an upcoming Q2 2026 earnings report on August 5, pushed Solventum shares towards their …

What To Expect From Labcorp’s (LH) Q2 Earnings

Labcorp (LH) is set to announce its Q2 earnings this Thursday. Analysts expect a 5.3% year-on-year revenue growth, a slowdown from the previous year, though the company generally met revenue expectations last quarter. Investor sentiment in the healthcare providers & services sector has been …

NeoGenomics, Inc. 2026 Q2 - Results - Earnings Call Presentation (NASDAQ:NEO) 2026-07-28

This article announces that NeoGenomics, Inc. published its Q2 2026 earnings call presentation. The company reported an EPS of $0.05, beating estimates by $0.02, and revenue of $201.66M, surpassing expectations by $4.67M and representing an 11.21% year-over-year increase. The presentation is related to their …

IQVIA Holdings (IQV) Soars on Revenue Growth Outlook, Strong Q2

IQVIA Holdings (IQV) saw its stock jump after reporting strong second-quarter results and raising its revenue growth outlook for the full year 2026. The company grew its revenues by 8.7% to $4.37 billion in Q2, contributing to an updated full-year projection of $17.275 billion …

DVA|DaVita Inc|Price:239.495|Chg%:+3.185

The article provides a comprehensive stock analysis of DaVita Inc (DVA) by TradingKey, highlighting its strong fundamentals, high growth potential, and fair valuation within the Healthcare Providers & Services industry. It notes DaVita's high institutional ownership, Warren Buffett's stake, and analysts' "Hold" rating with …

NeoGenomics anticipates $802M-$806M 2026 revenue as it targets mid-20% NGS growth and adjusts pharma expectations

Earnings Call Insights: NeoGenomics (NEO) Q2 2026 MANAGEMENT VIEW * "We're raising guidance because of these results as well as the underlying clinical strength we're seeing in the back half of this year." (CEO Anthony Zook) * "Total revenue in the quarter was $201.7 …

MDXH|MDxHealth SA|Price:0.400|Chg%:-0.011

This article provides a comprehensive stock analysis of MDxHealth SA (MDXH), highlighting its strong fundamentals and high growth potential despite recent weak market performance. The company is considered fairly valued within the Biotechnology & Medical Research industry and shows high institutional ownership. Analysts have …

Myriad Genetics Inc (MYGN) Financial Health: Profitability & Balance Sheet Analysis

Myriad Genetics Inc (MYGN) has a stable financial status and high operating efficiency, ranking 93rd out of 199 companies in the Healthcare Equipment & Supplies industry with a score of 7.30. The company reported a Q4 revenue of $200.40 million, marking a 2.30% year-over-year …

MEDP|Medpace Holdings Inc|Price:585.350|Chg%:+14.380

Medpace Holdings Inc (MEDP) closed at $585.35 on July 29, 2026, up 2.52%, with a market capitalization of $16.30 billion. The company exhibits strong fundamentals, high growth potential, and is considered fairly valued in the Biotechnology & Medical Research industry, where it ranks 65 …

Agilent to Announce Third-Quarter Fiscal Year 2026 Financial Results on Aug. 26

Agilent Technologies Inc. (NYSE: A) will release its third-quarter fiscal year 2026 financial results after the market closes on Wednesday, Aug. 26. The company will host a conference call on the same day at 1:30 p.m. PDT to discuss the results, which will be …